Independent register of U.S. FDA drug recalls · updated Oct 14, 2026
RxRecalls Get alerts

FDA Drug Recalls

14,806 recalls, newest first

Class III · Low risk

Meclizine hydrochloride tablets USP

Marketed without an approved NDA/ANDA: Bottles were released prior to final approval.

Terminated Unapproved drug Jubilant Cadista Pharmaceuticals, Inc. NDC 59746-122-06 D-0082-2018
Class I · High risk

Midazolam Injection

Labeling: Label MIX-UP. Blister Packages, Labeled as Midazolam injection, USP, 2 mg / 2 ml, Containing Syringes of Ondansetron Injection, USP, 4 mg / 2 mL

Terminated Labeling / mix-up Fresenius Kabi USA, LLC NDC 76045-001-20 D-0152-2018
Class II · Moderate risk

Estriol

cGMP Deviations: lack of quality assurance at the API manufacturer.

Terminated cGMP deviation Fagron, Inc NDC 51552-1392-5 D-0079-2018
Class II · Moderate risk

Dutasteride and Tamsulosin HCl Capsules

Failed dissolution specifications; all lots within expiry are being recalled due to out of specification dissolution results.

Terminated Dissolution failure Teva Pharmaceuticals USA NDC 0591-3771-30 D-0069-2018
Class II · Moderate risk

Succinylcholine 20 MG/ML INJ

Labeling: Incorrect or Missing Lot and/or Exp Date; incorrect expiration date on the labeling of the outer poly bag

Terminated Labeling / mix-up Ace Surgical Supply Co., Inc. D-0071-2018
Class III · Low risk

Clofarabine injection

Labeling: Incorrect or Missing Package Insert: authorized generic product was packaged with the incorrect insert for the brand name product Clolar (clofarabine) injection.

Terminated Labeling / mix-up Sanofi-Aventis U.S. LLC NDC 0955-1746-01 D-0056-2018

Recalls by year